Exchange: OTC·Updated 08:00 AM EDT

BVNRY ADRs for Bavarian Nordic

$10.44
$0.14
(1.34%)
Pre-Market
Prev Close $10.44
EarningsNov 13
Mkt Cap$2.38B
Vol122.00

About BVNRY

Bavarian Nordic A/S engages in the business of developing, manufacturing, and commercializing cancer immunotherapies and vaccines for infectious diseases. The firm is involved in cancer immunotherapy including cancer pipeline, which focuses on therapeutic vaccines for breast, lung, ovarian, and prostate cancer. The company was founded on July 1, 1992 and is headquartered in Hellerup, Denmark.
47

Neutral Sentiment

How do you feel about BVNRY?

Advertisement|Remove ads.